![]() | Up a level |
2019
Mulders, Peter F. A., Martinez-Pineiro, Luis, Heidenreich, Axel, Babjuk, Marko, Colombel, Marc, Colombo, Renzo, Radziszewski, Piotr, Korneyev, Igor ORCID: 0000-0001-7347-1901, Surcel, Cristian, Yakovlevi, Pavel, Witjes, J. Alfred, Caris, Christien, Schipper, Raymond, Witjes, Wim P. J., Villers, A., Malavaud, B., Rouboud, G., Grimm, M. O., Retz, M., Wagenlehner, F., Stenzl, A., Olbert, P., Niegisch, G., Hakenberg, O., Goebell, P., Wirth, M., Bolenz, C., Tubaro, A., Selli, C., Porena, M., Kerst, M., van Melick, H., Antoniewicz, A., Chlosta, P., Palou, J., Ponce Diaz-Reixa, J., Alonso Dorrego, J. M., Llorente, C., Fernandez-Gomez, J., Alvarez Maestro, M., Alvarez-Ossorio, J. L., Sanchez Chapado, M., Ribal, M., Guix, M., Bellmunt, J., Villacampa, F., Schraml, J., Zachoval, R., Sinescu, I, Stoica, L., Sakalo, V, Matveev, V, Alekseev, B., Komyakov, B. and Van den Steen, Peter
(2019).
Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial.
Eur. Urol. Focus, 5 (5).
S. 849 - 853.
AMSTERDAM:
ELSEVIER.
ISSN 2405-4569
2018
Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262
Merseburger, A., Carl, S., Feyerabend, S., Gleissner, J., Grimm, M. -O., Gruellich, C., Heidenreich, A., Heinrich, B., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Passler, L., Shetty, S., Golsorkhi, T., Ryan, C. and Chowdhury, S. (2018). TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 74 - 75. BASEL: KARGER. ISSN 2296-5262
Miller, K., Heinrich, D., O'Sullivan, J. M., Carles, J., Wirth, M., Nilsson, S., Huang, L., Kalinovsky, J., Heidenreich, A. and Saad, F. (2018). Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. S. 287 - 288. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2016
Heidenreich, A., O'Sullivan, J., Gillessen, S., Heinrich, D., Gratt, J., Levy, J., Miller, K., Nilson, S., Saad, F., Tucci, M., Wirth, M. and Carles, J. (2016). Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration resistant prostate cancer (mCRCP) patients treated in an international early access program (EAP). Oncol. Res. Treat., 39. S. 86 - 88. BASEL: KARGER. ISSN 2296-5262
Heidenreich, A., Saad, F., Caries, J., Gillessen, S., Heinrich, D., Gratt, J., Miller, K., Nilsson, S., O'Sullivan, J., Tucci, M. and Wirth, M. (2016). Effects of concomitant medication and baseline parameters on overall survival and safety in German metastatic castration-resistant prostate cancer patient subset treated with Radium-223 dichloride within the international early access program (iEAP). Oncol. Res. Treat., 39. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262
Heinrich, D., Gillessen, S., Heidenreich, A., Keizman, D., O'Sullivan, J. M., Carles, J., Wirth, M., Miller, K., Procopio, G., Gratt, J., Seger-Van Tol, M., Nilsson, S. and Saad, F. (2016). Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Saad, F., Heidenreich, A., Heinrich, D., Keizman, D., O'Sullivan, J. M., Carles, J., Wirth, M., Miller, K., Gratt, J., Seger-Van Tol, M., Nilsson, S. and Gillessen, S. (2016). Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041